NEW DELHI:
Drug major
Lupi on Wednesday announced the launch of its
Favipiravi
drug under the brand name 'Covihalt' for the treatment patients with mild to moderate
COVID-
19 symptoms
at
Rs
49
per
tablet
in
India.
Favipiravir has received authorisation from the
Drug Controller General of
India (DCGI) for emergency use,
Lupin said
in a regulatory filing.
Its Covihalt dosage strength has been developed keeping
in mind convenience of administration, it stated, adding that the
drug is available as 200 mg tablets
in the form of a strip of 10 tablets, and priced
at
Rs
49
per
tablet.
Lupin President -
India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise
in managing widespread community diseases like tuberculosis to proactively reach patients across
India and ensure access to Covihalt through its strong distribution network and field force.
On August 4, Sun Pharmaceutical Industries had launched
Favipiravir under the brand name ''FluGuard'' for the treatment of mild to moderate cases of
COVID-
19,
at
Rs 35
per
tablet
in
India.
Shares of
Lupin were trading 0.32
per cent higher
at
Rs 943.70 apiece on BSE.